AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39096236 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective reserve
Number of subjects: 404
Study 39096236 — intervention group
Group type: EXPERIMENTAL
Intervention: Current lifestyle
Number of subjects: 404
Study 39096236 — intervention group
Group type: COMPARATOR
Intervention: Cumulative exposure to age-related stressors and COVID-19 infection
Number of subjects: 404
Study 39096467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (CNB)
Number of subjects: 231
Study 39096467 — intervention group
Group type: COMPARATOR
Intervention: Other ASMs (including valproate, lacosamide, levetiracetam, topiramate)
Number of subjects: 231
Study 39096659 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS721744 (antisense therapy to block prekallikrein), one subcutaneous dose
Number of subjects: 111
Study 39096659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 39096895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 464
Study 39096924 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly guided therapy (MGT)
Number of subjects: 436
Study 39096924 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum-based chemotherapy
Number of subjects: 436
Study 39096929 — intervention group
Group type: EXPERIMENTAL
Intervention: iscalimab 150 mg
Number of subjects: 273
Study 39096929 — intervention group
Group type: EXPERIMENTAL
Intervention: iscalimab 300 mg
Number of subjects: 273
Study 39096929 — intervention group
Group type: EXPERIMENTAL
Intervention: iscalimab 600 mg
Number of subjects: 273
Study 39096929 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 273
Study 39097000 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) program based on cognitive behavioral therapy
Number of subjects: 400
Study 39097000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 39097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lung surgery
Number of subjects: 0
Study 39097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessments using Numeric Pain Rating Scale and Visual Analogue Scale score
Number of subjects: 0
Study 39097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Leicester Cough Questionnaire, Brief Pain Inventory, McGill Pain Questionnaire, EORTC QLQ-C30, HADS
Number of subjects: 0
Study 39097307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support adjusted according to PMI strategy for 48 hours
Number of subjects: 60
Study 39097313 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 60
Study 39097313 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 39097315 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing programme
Number of subjects: 244
Study 39097315 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (annual oral health awareness visit)
Number of subjects: 244
Study 39097328 — intervention group
Group type: EXPERIMENTAL
Intervention: EDACS score ≥16
Number of subjects: 167
Study 39097328 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score ≥1
Number of subjects: 167
Study 39097328 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score >88
Number of subjects: 167
Study 39097328 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score of 0
Number of subjects: 167
Study 39097413 — intervention group
Group type: EXPERIMENTAL
Intervention: Davoceticept monotherapy (0.001-10 mg/kg, intravenous, Q1W or Q3W)
Number of subjects: 87
Study 39097413 — intervention group
Group type: EXPERIMENTAL
Intervention: Davoceticept and pembrolizumab combination (davoceticept 0.1 or 0.3 mg/kg, intravenous, Q1W or Q3W; pembrolizumab 400 mg every 6 weeks)
Number of subjects: 87
Study 39097413 — intervention group
Group type: EXPERIMENTAL
Intervention: Davoceticept monotherapy and combination with pembrolizumab
Number of subjects: 87
Study 39097467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab-plus-ipilimumab
Number of subjects: 1166
Study 39097467 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1166
Study 39097500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab ± ipilimumab second-line immunotherapy
Number of subjects: 66
Study 39097549 — intervention group
Group type: EXPERIMENTAL
Intervention: GB05 (1.2 million IU)
Number of subjects: 35
Study 39097549 — intervention group
Group type: EXPERIMENTAL
Intervention: GB05 (1.8 million IU)
Number of subjects: 35
Study 39097549 — intervention group
Group type: COMPARATOR
Intervention: GB05 (0.2 million IU)
Number of subjects: 35
Study 39097549 — intervention group
Group type: COMPARATOR
Intervention: GB05 (0.6 million IU)
Number of subjects: 35
Study 39097549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 39097566 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized insulin dosing using reinforcement learning for high-fat meals
Number of subjects: 15
Study 39097566 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized insulin dosing using reinforcement learning for meals followed by aerobic exercises
Number of subjects: 15
Study 39097695 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training in a movement amplification environment (experimental group)
Number of subjects: 36
Study 39097695 — intervention group
Group type: COMPARATOR
Intervention: Locomotor training in a traditional treadmill environment (control group)
Number of subjects: 36
Study 39097718 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during port and vein punctures
Number of subjects: 57
Study 39097718 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 57
Study 39097733 — intervention group
Group type: EXPERIMENTAL
Intervention: FamPALcare intervention (five telephone coaching sessions on HF home, palliative, and end-of-life care)
Number of subjects: 39
Study 39097733 — intervention group
Group type: EXPERIMENTAL
Intervention: FamPALcare intervention
Number of subjects: 39
Study 39097733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 39097739 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal activity (EDA) and electrocardiogram (ECG) signals
Number of subjects: 64
Study 39097739 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable regression analysis
Number of subjects: 64
Study 39097739 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering analysis
Number of subjects: 64
Study 39097739 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective pain perception
Number of subjects: 64
Study 39097916 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoimmunotherapy (nCIT)
Number of subjects: 81
Study 39097916 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (nCT)
Number of subjects: 81
Study 39097924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg three times daily (TET-T)
Number of subjects: 406
Study 39097924 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 500 mg four times daily (TET-F)
Number of subjects: 406
Study 39097970 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki intervention applied for three sessions of 35-40 minutes on postpartum 1st, 2nd, and 7th days
Number of subjects: 86
Study 39097970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Reiki intervention)
Number of subjects: 86
Study 39098048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated human amniotic/chorionic membrane (dHACM) treatment following excisional debridement
Number of subjects: 4
Study 39098315 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with heterozygous familial hypercholesterolaemia
Number of subjects: 3506
Study 39098315 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with heterozygous familial hypercholesterolaemia
Number of subjects: 3506
Study 39098315 — intervention group
Group type: COMPARATOR
Intervention: Males compared to females
Number of subjects: 3506
Study 39098321 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fosravuconazole
Number of subjects: 104
Study 39098321 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg fosravuconazole
Number of subjects: 104
Study 39098321 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (control)
Number of subjects: 104
Study 39098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of fosravuconazole
Number of subjects: 104
Study 39098325 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus ≤6 monthly incentives (22,500 Tanzanian Shillings, about US$10 each), conditional on visit attendance.
Number of subjects: 1990
Study 39098325 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1990
Study 39098432 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative single-dose partial breast irradiation (PBI) followed by breast-conserving surgery (BCS)
Number of subjects: 36
Study 39098454 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-treatment levels of IL-6 (quartile 4 versus 1)
Number of subjects: 1208
Study 39098454 — intervention group
Group type: EXPERIMENTAL
Intervention: Global CRF of clinical importance (EORTC QLQ-C30 ≥40/100)
Number of subjects: 1208
Study 39098454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment inflammatory markers
Number of subjects: 1208
Study 39098658 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment in HR patients
Number of subjects: 441
Study 39098658 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment in VHR patients
Number of subjects: 441
Study 39098658 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention in VHR patients
Number of subjects: 441
Study 39098658 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure in VHR patients
Number of subjects: 441
Study 39098658 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, BMI, and HbA1c in HR patients
Number of subjects: 441
Study 39098761 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-racemic amisulpride (SEP-4199) in a phase 2 placebo-controlled trial
Number of subjects: 2026
Study 39098761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2026
Study 39099085 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-aQIV and RSVPreF3 OA co-administration (Co-Ad)
Number of subjects: 1045
Study 39099085 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of FLU-aQIV and RSVPreF3 OA (Control)
Number of subjects: 1045
Study 39099093 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA
Number of subjects: 1152
Study 39099093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1152
Study 39099801 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis
Number of subjects: 0
Study 39099801 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 39100428 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education plus behavior contract (n = 91)
Number of subjects: 173
Study 39100428 — intervention group
Group type: COMPARATOR
Intervention: Standard education (n = 82)
Number of subjects: 173
Study 39100527 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 417
Study 39100527 — intervention group
Group type: EXPERIMENTAL
Intervention: High number of sexual partners
Number of subjects: 417
Study 39100571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day) for 8 weeks
Number of subjects: 67
Study 39101114 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB-based PCI
Number of subjects: 360
Study 39101114 — intervention group
Group type: COMPARATOR
Intervention: DES-only PCI
Number of subjects: 360
Study 39101128 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Number of subjects: 197
Study 39101128 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc
Number of subjects: 197
Study 39101128 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIIFc/rFIXFc
Number of subjects: 197
Study 39101201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 37
Study 39101201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 39101209 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications (including delayed gastric emptying)
Number of subjects: 528
Study 39101209 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavien-Dindo grade 3b to 4 complications
Number of subjects: 528
Study 39101209 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3b and 4 complications in pancreatic cancer patients
Number of subjects: 528
Study 39101472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran as adjunct to high-intensity statin therapy with or without ezetimibe
Number of subjects: 0
Study 39101472 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe as adjunct to high-intensity statin therapy
Number of subjects: 0
Study 39101472 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab as adjunct to high-intensity statin therapy and ezetimibe
Number of subjects: 0
Study 39101472 — intervention group
Group type: COMPARATOR
Intervention: Placebo as adjunct to high-intensity statin therapy with or without ezetimibe
Number of subjects: 0
Study 39101506 — intervention group
Group type: COMPARATOR
Intervention: Behavioural support or system-change interventions
Number of subjects: 9959
Study 39101506 — intervention group
Group type: COMPARATOR
Intervention: Warm handoff system-change intervention
Number of subjects: 9959
Study 39101506 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 9959
Study 39101506 — intervention group
Group type: COMPARATOR
Intervention: Behavioural support plus nicotine replacement therapy (NRT)
Number of subjects: 9959
Study 39101506 — intervention group
Group type: COMPARATOR
Intervention: Behavioural support plus NRT
Number of subjects: 9959
Study 39101607 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT (Surgery with Postoperative Physical Therapy)
Number of subjects: 97
Study 39101607 — intervention group
Group type: COMPARATOR
Intervention: CO (Crossover from PTA to SPT)
Number of subjects: 97
Study 39101607 — intervention group
Group type: COMPARATOR
Intervention: PTA (Physical Therapy Alone)
Number of subjects: 97
Study 39101654 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (NAIT)
Number of subjects: 47
Study 39101698 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab every 2 weeks (SECQ2W)
Number of subjects: 1084
Study 39101698 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab every 4 weeks (SECQ4W)
Number of subjects: 1084
Study 39101698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study 39101738 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy in addition to exercise therapy (n=150)
Number of subjects: 150
Study 39101738 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy alone (n=150)
Number of subjects: 150
Study 39101915 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Addiction Symptom Inventory (FASI)
Number of subjects: 0
Study 39101915 — intervention group
Group type: COMPARATOR
Intervention: Yale Food Addiction Scale (YFAS)
Number of subjects: 0
Study 39102049 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 2400 mg/day
Number of subjects: 23
Study 39102049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 39102111 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and low glycemic load diet (1.3-1.4 g/kg/day)
Number of subjects: 120
Study 39102111 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (0.8-1.0 g/kg/day of protein)
Number of subjects: 120
Study 39102242 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm using full FAF images as benchmark
Number of subjects: 0
Study 39102242 — intervention group
Group type: COMPARATOR
Intervention: Ablation experiments with No Lesion, No Rim, and No Background datasets
Number of subjects: 0
Study 39102242 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex Hull dataset to evaluate lesion size
Number of subjects: 0
Study 39102249 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (physiotherapy plus cognitive behavioral therapy)
Number of subjects: 40
Study 39102249 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (psychological support intervention)
Number of subjects: 40
Study 39102302 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39102464 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults exposed to 40°C, 9% relative humidity
Number of subjects: 83
Study 39102464 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults exposed to a range of conditions (31°C-40°C, 9-45% RH)
Number of subjects: 83
Study 39102464 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults in 40°C, 9% RH
Number of subjects: 83
Study 39102464 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults in 40°C, 9% RH
Number of subjects: 83
Study 39102622 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT plus systemic therapy
Number of subjects: 40
Study 39102622 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (control)
Number of subjects: 40
Study 39102624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 906
Study 39102624 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year
Number of subjects: 906
Study 39102712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body medicine stress management and lifestyle modification (MBM) program, duration 9 months, guided intervention group (IG)
Number of subjects: 0
Study 39102712 — intervention group
Group type: COMPARATOR
Intervention: Self-guided waitlist control group (CG)
Number of subjects: 0
Study 39102712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body medicine program (both guided and self-directed)
Number of subjects: 0
Study 39102756 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab, apatinib, and capecitabine combination therapy
Number of subjects: 28
Study 39102832 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 551
Study 39102832 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 551
Study 39103234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of monofocal and EDOF IOL implantation
Number of subjects: 88
Study 39103234 — intervention group
Group type: COMPARATOR
Intervention: Bilateral monofocal IOL implantation
Number of subjects: 88
Study 39103472 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measurement
Number of subjects: 235
Study 39103508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempus xT CDx assay for detecting HLA LOH
Number of subjects: 10982
Study 39103508 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A LOH
Number of subjects: 10982
Study 39103508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempus AWARE program
Number of subjects: 10982
Study 39103546 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (30% sunflower seed flour)
Number of subjects: 11
Study 39103546 — intervention group
Group type: EXPERIMENTAL
Intervention: WWC (30% whole wheat flour)
Number of subjects: 11
Study 39103546 — intervention group
Group type: COMPARATOR
Intervention: CC (control cracker with conventional flour)
Number of subjects: 11
Study 39103546 — intervention group
Group type: COMPARATOR
Intervention: Glucose reference drink
Number of subjects: 11
Study 39103661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised modified cyanoacrylate (1 mL) for anastomotic reinforcement
Number of subjects: 152
Study 39103661 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement (control group)
Number of subjects: 152
Study 39103782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bilateral parasternal block (PSB) and serratus anterior plane block (SAPB)
Number of subjects: 20
Study 39103816 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Fatigue (IMFG)
Number of subjects: 24
Study 39103816 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation
Number of subjects: 24
Study 39103816 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 39103897 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge Graphs
Number of subjects: 0
Study 39103897 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-defined mutational 10-gene signature
Number of subjects: 0
Study 39103901 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 320/14.4/10 µg
Number of subjects: 0
Study 39103901 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 µg
Number of subjects: 0
Study 39103901 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol fumarate dihydrate (BFF) 320/10 µg
Number of subjects: 0
Study 39103923 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise-intensity prescription targeting pleasure
Number of subjects: 47
Study 39103923 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise sessions based on the FITT principle
Number of subjects: 47
Study 39103928 — intervention group
Group type: EXPERIMENTAL
Intervention: Verticalization to 90°
Number of subjects: 30
Study 39103928 — intervention group
Group type: EXPERIMENTAL
Intervention: Verticalization beyond 30°
Number of subjects: 30
Study 39103928 — intervention group
Group type: COMPARATOR
Intervention: Baseline position (30° semi-seated)
Number of subjects: 30
Study 39103940 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast echocardiography (transthoracic echocardiography, TTE)
Number of subjects: 68
Study 39103940 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (control group)
Number of subjects: 68
Study 39103947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high-frequency (10 Hz) rTMS sessions over the Primary Motor Cortices
Number of subjects: 40
Study 39103947 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided neurofeedback sessions focused on reducing average bilateral alpha and beta bands
Number of subjects: 40